Axinn is the go-to firm for IP matters of strategic importance.  The firm has numerous seasoned IP trial lawyers, typically has several dozen patent cases pending at a time, tries multiple patent cases annually and has served as lead counsel in some of the most significant recent patent trials, including the defense of a multi-billion dollar jury trial.  On many occasions, the firm has been asked to take over pending cases and serve as lead trial counsel.  

Axinn attorneys also offer exceptional depth of technical training and patent counseling experience.  Axinn seeks to partner with its clients in the ongoing management of their IP portfolios, product launches and defensive issues.  To help its clients execute their business plans, the firm marshals all of its skills and experience in law, science, business and (when necessary) litigation. 

Axinn offers skills and experience in numerous industries and technologies, including all areas of life sciences, chemicals, mechanical, electronics and software.  In addition, the firm has an extensive FDA litigation and counseling practice.

Axinn is also well-positioned to handle issues and cases at the intersection of antitrust and intellectual property.  The firm regularly litigates antitrust counterclaims in IP cases, and counsels clients on issues such as patent pooling, the legality of settlement and license agreements and patent misuse.

News

• Axinn and IP Partners Ranked by IAM Patent 1000: The World’s Leading Patent Professionals
• Axinn Moves Washington, D.C. Office to New LEED Gold Status and WELL Certified Space
• Nine Axinn Attorneys Named to Capital Pro Bono Honor Roll
• Axinn Partner Stacie Ropka Named to The Center for Biosimilars’ Board of Advisors
• Axinn Recognized in Ten Categories of "Best Law Firms" Report
• The District of Columbia Courts Recognize Four Axinn Attorneys in its 2019 Capital Pro Bono Honor Roll
• Matthew Becker Named an Intellectual Property Trailblazer by The National Law Journal
• Three Axinn partners named "Life Sciences Stars" in LMG Life Sciences 2020
• The 2021 Edition of Benchmark Litigation has selected Axinn as a “Recommended Firm” and named four Axinn partners as IP “Litigation Stars” in CT and DC
• Axinn Attorneys Named to Best Lawyers 2021
• Managing IP STARS Selected Axinn IP Partner Jeannine Yoo Sano as a 2020 Patent Star in CA and Recommended Axinn in CT for IP
• Axinn and IP Partners Ranked by IAM Patent 1000: The World’s Leading Patent Professionals
• Jeannine Yoo Sano Named a Profiles in Diversity Journal Woman Worth Watching
• Chambers USA 2020 Recognizes Axinn Lawyers and Practice Groups
• Chad Landmon Named to NLJ’s List of Healthcare/Life Sciences Trailblazers
• Axinn Continues West Coast Expansion with Addition of Three Senior Intellectual Property Litigators
• Federal Circuit Affirms Axinn’s Trial Victory for Alvogen
• Axinn Recognized in Nine Categories of "Best Law Firms" Report
• Paul Zeineddin Joins Axinn’s Intellectual Property Group in Washington, D.C. Office
• Chad Landmon named a "Life Sciences Star" in LMG Life Sciences 2019
• The 2020 Edition of Benchmark Litigation has selected Axinn as a “Recommended Firm” and named four Axinn partners as IP “Litigation Stars” in CT and DC
• Axinn Partners Named to Best Lawyers 2020
• Axinn Received Outstanding Achievement Award for Pro Bono Work
• Chambers USA 2019 Recognizes Axinn Lawyers and Practice Groups
• Axinn’s Client Awarded Attorneys’ Fees in “Exceptional” PIV Case
• Axinn Obtains Favorable Settlement for Pro Bono Client
• Connecticut Law Tribune Honors Axinn With Two Professional Excellence Awards
• Axinn Named a "Legal Lion" for Federal Circuit Patent Win
• Axinn Promotes Josh Reisberg to Partner, Bradley Justus and Matt Murphy to Counsel
• Axinn Recognized in Nine Categories of "Best Law Firms" Report
• Axinn Launches California Office, Bringing Elite Antitrust and IP Practices to West Coast
• Axinn Successfully Secures Asylum for Pro Bono Client
• Axinn Named "Intellectual Property Firm to Watch" at the LMG Life Sciences Awards 2018
• Axinn Leads Alvogen to Victory in Hatch-Waxman Case for Generic Zohydro^®
• Eight Axinn Partners Named to Best Lawyers 2019
• Axinn Sponsors Travelers Championship 2018
• Axinn Successfully Defeats a Motion to Dismiss on Behalf of Pro Bono Client
• Chambers USA Recognizes Axinn Practice Groups
• Chambers USA Recognizes Seven Axinn Partners
• Axinn Sponsors Genomics Lab at Connecticut Science Center
• Stacie Ropka Named Among Hartford Business Journal's Remarkable Women in Business
• The Connecticut Law Tribune Honors Two Axinn Attorneys
• New York State Bar Recognizes Twelve Axinn Attorneys
• Axinn Promotes Jeny Maier and Jason Murata
• Axinn Recognized in Eight Categories of "Best Law Firms" Report
• Seven Axinn Partners Named to the 2018 List of Best Lawyers in America
• Federal Circuit Rules for Axinn Client in Abilify Patent Appeal
• Axinn Sponsors Travelers Championship
• Chambers USA Recognizes Axinn Practice Groups
• Six Axinn Partners Recognized by Chambers USA
• Dr. Stacie Ropka Identified as a Woman Worth Watching in STEM^® Award Winner
• Axinn Promotes Stacie Ropka and Jeny Maier
• Axinn Successfully Argues for Claim Construction in Mayne v. Merck
• Axinn Successfully Obtains Dismissal of Certain Patent Claims asserted against Zydus Pharmaceuticals in Boehringer Ingelheim Pharmaceuticals, Inc. v. HEC Pharma Co., Ltd.
• Axinn Earns Six Tier 1 Categories in "Best Law Firms"
• Axinn Named IP Litigation Department of the Year
• Six Axinn Partners Named to the 2017 List of Best Lawyers in America
• Axinn Defeats TRO, Enabling Immediate Launch of Generic Versions of AstraZeneca’s Blockbuster Crestor
• Axinn Named to The National Law Journal’s 2016 Midsize Hot List
• Axinn Obtains Stipulated Summary Judgment of Non-Infringement for Zydus
• Axinn Expands IP and Regulatory Practice with Partners David Silverstein and Aziz Burgy
• Axinn Recognized in Six Categories of "Best Law Firms" Report
• Axinn Successfully Obtains Dismissal for Zydus Pharmaceuticals
• Axinn Partners Named to the 2016 List of Best Lawyers in America
• Axinn Obtains Denial of a TRO Motion for Client Zydus
• Axinn Partners Ranked by Chambers in Global Guide
• Axinn Named Litigation Department of the Year
• Axinn Promotes Rachel Adcox and John Tanski to Partner; Thomas Hedemann to Counsel
• Axinn Successful In Protecting FDA Approval for Client Endo Pharmaceuticals Inc.
• Axinn Earns Six Tier 1 Categories in "Best Law Firms"
• Matt Becker, Jim Veltrop, John Briggs, Steve Axinn and Fran Morrison Named to the List of 2015 Best Lawyers in America
• Jason Murata Selected as New Leader in the Law
• Axinn Granted Summary Judgment in Delaware Federal Court
• Axinn Named to The National Law Journal's Midsize Hot List
• Axinn Honored With Litigation Department of the Year
• Federal Circuit Rules for Axinn Client in Tamiflu Patent Appeal
• Chad Landmon Named to Law360's Intellectual Property "Rising Star" List
• Entire Market Value Rule Vs. 'Convoyed Sales' Rule
• Longtime FTC Veteran Richard Dagen Joins Axinn
• Axinn Promotes Daniel Bitton and Stacie Ropka
• Axinn Wins $16 Million Damages Award for Medical Device Client at Jury Trial in Delaware
• Chad Landmon Receives University of Connecticut Distinguished Alumni Award
• Chad Landmon Named to Law360's Life Sciences "Rising Star" List
• Axinn Obtains Favorable Decision in FDA Suit
• Axinn Partner Chad Landmon Honored as a "New Leader in the Law"
• Axinn Obtains Summary Judgment Victory Against FDA
• Axinn Assisted Actavis in Resolving Ten-Year-Old Dispute with Pfizer
• Axinn Successful in Protecting Client Alvogen's Entry to Drug Market
• Axinn Partners Named Connecticut "Rising Stars" 2011/2012
• Axinn Partner Chad Landmon Honored as Hartford Business Journal “40 Under 40” Winner
• Axinn Partner Pens Article on Biosimilar Approval Standards Under BPCI
• On March 17, 2011, Chad Landmon Discussed Bioequivalence at ACI's FDA Boot Camp
• On February 3, 2011, Chad Landmon Presented on the FDA Hearings on the BPCI Act at the AIPLA Mid-Winter Institute
• Matthew Becker Speaks With PharmaWire on the Potential Patent Life of BTC and Johnson & Johnson’s Abiraterone Drug For Prostate Cancer
• Chad Landmon Presented on Bioequivalence in Boston
• Axinn Partner Chad Landmon Speaks with Pharmawire about Johnson & Johnson Facing Further Regulatory Scrutiny
• Axinn's Partner Chad A. Landmon Quoted by The Pink Sheet Discussing the Lovenox Lawsuit
• Landmon Quoted by Pharmawire on the Possibility of a Cephalon Settlement
• Landmon Provides Insights on Generics Challenge of AstraZeneca's Crestor Patents to Pharmawire
• Landmon Discusses Teva's Launch of Generic Cozaar/Hyzaar With Market Exclusivity with The Pink Sheet
• Chad Landmon Discusses a Recent U.S. Court of Appeals Ruling with The Pink Sheet
• Axinn Wins Summary Judgment on Behalf of Mutual Pharmaceutical Company
• Axinn Partner Chad Landmon Discusses "pay-for-delay" Legislation in White House Health Care Plan
• Axinn's Chad Landmon Discusses the Likelihood of the FTC Increasing Efforts to Obtain Passage of "Pay-For-Delay" Legislation with Drug Industry Daily
• Chad Landmon Discusses At-Risk Launches with The Pink Sheet Daily
• Chad Landmon Discusses Report on Generic Drug Availability with Generic Line
• Chad Landmon Discusses Astellas Court Loss with Generic Line
• Chad Landmon Discusses Cubist's Lawsuit Against Teva with Pharmawire
• Axinn's Chad Landmon Speaks with Drug Industry Daily About the Drug Price Competition Act of 2009
• Chad Landmon Participates in Question and Answer Session with The National Law Journal on Follow-On Biologics
• Chad Landmon Discusses Court Decision Enjoining Teva from Launching Generic Osteoporosis Drug with Generic Line
• Chad Landmon Discusses Novartis’ Exjade^® with Pharmawire
• Chad Landmon Discusses Court Rulings and Patent Law Reform with Thomson-Reuters
• Chad Landmon Discusses Teva's At-Risk Launch of Generic Pulmicort with The Pink Sheet
• Chad Landmon Discusses FDA's Letter Ruling Practice with The Pink Sheet
• CBI's Pharmaceutical Congress on Paragraph IV Disputes -- Chad Landmon Discusses Litigation Strategies, Generic Exclusivity Forfeiture and Recent Developments in Paragraph IV Disputes
• Chad Landmon Discusses Recent Declaratory Judgment Ruling with The Pink Sheet
• Pfizer Buys More Time for Lipitor
• Matt Becker participates in GC New England Rountable on Patent Litigation
• Law Article May Spark Patent Litigation Strategy
• The Best and Worst Patents for Generics to Fight
• Chad Landmon Discussess generic exclusivity forfeiture provisions with IP Law360
• Michael Keeley and Chad Landmon discuss FDA's recent 180-day exclusivity decisions with FDAnews
• FDAnews Audioconference -- Navigating the FDA's New 180-Day Generic Marketing Exclusivity Rulings
• Firm Gears Up For High Stakes Drug Lit
• Jim Veltrop Featured in IP360
• Cantor Colburn's Michael Cantor plugs Jim Veltrop in IP Law 360
• IP Litigation: Fran Morrison Comments on Qualcomm Legal Issues in Wall Street Journal and The Recorder
• Axinn Represents INEOS in U.S. Litigation
• Axinn Serving as Patent Counsel for ADHD and Pain Relief Medications
• Axinn Continues to Expand Its Intellectual Property Group
• Axinn Represents URL/Mutual Companies in Launch of Guaifenesin Products
• Axinn Defends Fila in Marshall, Texas Patent Action
• Axinn Expands Its Intellectual Property Group
• Axinn Represents Sport Brands International/FILA in Connection with Launch of Various Products
• Axinn Represents R.R. Donnelly in Patent and Antitrust Litigation
• Axinn Represents Purepac Pharmaceutical Company in Metformin Launch
• Axinn Represents Stanley Works in Patent Litigation
• Stanley Defends Its Colors, Trade Turfs
• Axinn Defends Ryobi Technologies, Inc.
• View More ›

Articles & Newsletters

• SCOTUS Decides Arthrex: Much Ado About Inter Partes Reviews
• The Center for Biosimilars Interview: Axinn IP Chair Provides Analysis of Biden Biosimilars Initiative
• New U.S. Legislation Creates Momentum for Biosimilars
• Pharmacy Times Interviews
• Will Skinny Labelling Survive?
• IP and Collaboration
• Interview on the FDA’s Emergency Use Authorization Process for COVID-19 Vaccines
• Axinn IP Update: Where is the Federal Circuit Heading in the Skinny Labeling Case?
• A Look at What’s Ahead in the Rapidly Growing Cell Therapy Landscape
• Axinn IP Update: Federal Circuit Says Functional Patent Claims Must Clear "High Hurdles"
• Axinn IP Update: Federal Circuit Agrees to Reconsider Controversial “Skinny Label” Decision
• Member Spotlight: Francis H. Morrison
• How President-Elect Biden’s Cabinet Nominations May Impact Pharmacy This Year
• Susceptibility of Digital Products to Section 271(g) in the Age of Cloud Computing, Artificial Intelligence, Blockchains, and 3D Printing
• Frandly Fire
• When Japanese Witnesses Testify in U.S. Courts: Answers to Nine Common Concerns
• Our Journey to Voting by Mail-In Ballot in North Carolina in 2020
• How Justice Barrett’s Confirmation Might Impact Patent Eligibility
• Top 10 IPR Pitfalls at the Institution Stage
• What the Potential Elimination of the Biologics Price Competition and Innovation Act Means for Pharmacy
• Axinn FDA Update: Insights on the MODERN Labeling Act
• Seeking "Mens Sana in Corpore Sano" in a Pandemic
• Legal Opinion: BPCIA is Likely to Survive Latest ACA Challenge
• How to Protect IP Against COVID-19 Scammers Leveraging Social Media Algorithms to Legitimize Fake Products
• The 2020 Axinn Survey of U.S. Litigation Involving Japanese Companies
• Surveying the Landscape
• Axinn FDA Update: A Difficult Analysis Is Not Necessarily a Deferential Analysis
• Tuning in to Covered Business Method Review's Series Finale
• Inclusion Matters, Now More Than Ever: Practical Suggestions for Making a Difference
• Axinn IP Update: District Court Retains Subject Matter Jurisdiction But Grants Dismissal After Paragraph III Conversion
• IPR: The End of the Road for Fifth Amendment Challenges?
• Old Drug, New Tricks? How the BPCIA Could Increase Generic Competition for Insulins
• A Close Look at European Union's AI Regulation Proposal
• How to Combat IP-Facilitated Digital Fraud During Pandemic
• The 2019 Axinn Survey of U.S. Litigation Involving Japanese Companies
• Balancing Settlements, Motions After Fed. Circ. Serta IP Ruling
• Axinn IP Update: Six Patents Directed to Humanized Monoclonal Antibodies Fall at PTAB
• Axinn IP Update: Settlement Practice in Light of Pending Motions
• Pharmaceutical Experience Matters in Defending Pharmaceutical Securities Cases
• Axinn IP Update: SCOTUS Passes on Refining Subject Matter Eligibility Doctrine
• Axinn IP Update: No “Single-Entity” Requirement for Section 271(g) Liability
• Axinn IP Update: Federal Circuit Addresses BPCIA Safe Harbor, Damages
• Fed Circ. Ruling May Affect Eligibility of Life Sciences Patents
• Axinn IP Update: Section 287(c) Immunity Has Its Limits
• Curing the Drug Label as Prior Art Malady at the PTAB
• New Calif. Pay-For-Delay Law May Hurt Those It Aims to Help
• Protecting Intellectual Property in the Era of Intelligent Machines
• Axinn IP Update: No Collateral Estoppel after PTAB Ruling on IPR
• Failure to Launch: The Patent Thicket Delay of US Biosimilars
• Axinn IP Update: PTAB Abused its Discretion in Denying Patentee Leave to Correct Chain of Priority
• Fed. Circ. Muddies Waters on Method-Of-Treatment Patents
• Fixing the Follow-On Insulin Regulatory Approval "Dead Zone"
• Axinn IP Update: Federal Circuit Says Method of Treatment Claims Are Not Per Se Eligible Under Section 101
• Axinn Insights on U.S. Litigation for Japanese Companies: The Duty to Preserve Documents and Implement Litigation Holds in U.S. Civil Litigation
• Biologic Labels and Induced Patent Infringement: A Perspective on Evolving U.S. Law
• Justices May Be Ready to Narrowly Overturn 'Auer'
• Axinn IP Update: Hikma Pharmaceuticals USA, Inc. v. Vanda Pharmaceuticals, Inc.
• Axinn IP Update: U.S. Supreme Court Holds That Copyright Office Must Grant Copyright Registration Before Infringement Suit Can Be Filed
• Method-of-Treatment Patent Eligibility: Step 1 and Done?
• A Hard Choice for Abbreviated Biologics License Applicants
• Axinn IP Update: Federal Circuit Affirms No Public Use Via Implied Confidentiality
• Axinn IP Update: U.S. Supreme Court Ruling Leaves On-Sale Bar Unchanged
• Patent Dance Developments: A Tale of 2 Antibodies
• Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio, Second Edition
• The CRISPR Tug of War
• Beyond the Merits: Generic Company Defense Strategies
• Integrating Trade Secrets into a Comprehensive IP Strategy
• 2017 Federal Circuit Obviousness Decisions in Biopharma: 5 Takeaways
• Using Digital Tools in Litigation
• Joint Infringement Post-Akamai Part Two: Decisions Since Akamai and Practice Insights
• Joint Infringement Post-Akamai Part One: Exploring the New Joint Infringement Standard
• How Much Detail Should You Provide in a Patent Infringement Complaint?
• Recent Developments in Japanese and U.S. Trade Secret Laws
• Data Analytics to Identify Hot Spots in Obviousness Challenges
• FDA Regulation of HCT/Ps – Impact of New Guidances on Manufacturers and Users
• Now Comes The Hard Part: Sandoz Must Sell Its Biosimilar
• A Call for Antibody Quality Control
• 5 Lessons We Can Learn from FDA’s First Biosimilar Review
• Protecting Business Trade Secrets When Working Abroad
• Should The Entire Market Value Rule Apply To Lost Profits?
• Law360's Q&A With Axinn's Matthew Becker
• 2012 Court Decisions Impact the Life Science Industry
• Use of License Agreements to Determine Reasonable Royalties
• Brand's Off-Label Promotion: Valuable Tool for Generics
• Innovative Procedures v. Premarketing Approval
• Machine-Or-Transformation Test After Myriad: Implications To The Prosecution Of Process Claims
• Heightened Standard For The Entire Market Value Rule?
• Human Tissue and Stem Cell Therapies: Revolutionary New Therapies that Face Increasing FDA Scrutiny
• Federal Circuit Draws the Line on DJ Jurisdiction
• FDA's Exclusivity Forfeiture Saga Continues
• Raising the Bar of Patentability
• Here Comes The Tidal Wave of Generic DJ Actions
• FDA Removes Teeth From Exclusivity Forfeiture
• What is Patentable?
• Supreme Court Backhands Key Federal Circuit Test
• FTC Rules That Deception Regarding Patents During Standard Setting Process Violates Antitrust Laws
• Fourth Circuit Rejects Another Authorized Generics Challenge
• On Demand: Focusing The Patent Scope
• FDA's "Holding On The Merits" Test
• Recent Court Rulings Indicate That Patent Rights May Trump the Antitrust Laws
• Supreme Court Abandons Presumption of Market Power in Patent-Tying Cases
• The "Narrowed Claim Conundrum" Resulting from Reissue and Reexamination Proceedings
• The Impact of a Brand Generic Launch on the Recovery of Patent Damages
• "Schering" Overruled: Risk of Settling Patent Suits Reduced?
• Invention is the Mother of Litigation
• Trade Secret Misappropriation A Federal Crime
• View More ›